In 2023, the number of confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in the UK was the baseline for the projected trend. From 2024 to 2028, there is a projected annual decline in cases: from 42 in 2024 down to 37 by 2028. The year-on-year variation shows a steady decrease in cases, with the compound annual growth rate (CAGR) indicating a downward trend in the number of RR-/MDR-TB cases over five years.
Future trends to watch for include advancements in TB treatment, policy changes in healthcare, and enhanced public health measures. These factors could expedite the reduction of drug-resistant TB cases more significantly.
